Immupharma PLC Appointment of Joint Broker (7347G)

TIDMIMM

RNS Number : 7347G

Immupharma PLC

03 July 2012

FOR IMMEDIATE RELEASE 3 JULY 2012

ImmuPharma PLC

Appointment of Cenkos Securities as Joint Broker

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug development company, is pleased to announce the appointment of Cenkos Securities plc, as Joint Broker to the Company, with immediate effect.

Commenting on the appointment of Cenkos, Dimitri Dimitriou, ImmuPharma's Chief Executive Officer said: "We are delighted to be working more closely with Cenkos. The Cenkos team brings a wealth of experience within the capital markets arena as well as a strong franchise in healthcare which should be invaluable for ImmuPharma through this next important stage of our development where we are focusing on advancing our lead compounds in Lupus and Cancer and also further strengthening our shareholder relationships. The proactive approach that Cenkos has with regards to marketing its corporate stocks combined with its high level analyst research will undoubtedly add a positive dimension to this strategy."

For further information please contact:

 
 ImmuPharma PLC 
 Dimitri Dimitriou, Chief Executive Officer    +44 20 7152 4080 
 Lisa Baderoon, Head of Investor Relations     +44 7721 413 496 
 
 Buchanan                                      + 44 20 7466 5000 
 Mark Court 
 
 Cenkos Securities plc                         +44 20 7397 8900 
 Stephen Keys, Camilla Hume (Corporate 
  Finance) 
  Andy Roberts (Sales)

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUUVRRUOABRUR

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024